FIELD: biotechnology.
SUBSTANCE: proposed is a single variable immunoglobulin domain capable of binding to human serum albumin. Also proposed are a therapeutic construct including said single variable domain and a pharmaceutical composition including said construct. The invention also relates to nucleic acids, host cells and methods for producing a single variable immunoglobulin domain or a construct including said domain.
EFFECT: invention provides improved pharmacokinetic parameters of binding to human serum albumin.
24 cl, 13 dwg, 6 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADVANCED SERUM ALBUMIN BINDING AGENTS | 2018 |
|
RU2797270C2 |
| IMPROVED SUBSTANCES BINDING TO SERUM ALBUMIN | 2018 |
|
RU2789495C2 |
| IMPROVED VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2015 |
|
RU2746738C2 |
| IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS | 2015 |
|
RU2809788C2 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| PHARMACEUTICAL COMPOSITION, INCLUDING A PH20 VARIANT OF HUMAN HYALURONIDASE, AND A MEDICINAL PRODUCT FOR SUBCUTANEOUS ADMINISTRATION | 2020 |
|
RU2810952C2 |
| IMMUNOGLOBULINS BINDING AGGRECAN | 2018 |
|
RU2771818C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
